Volume 56, Pages S54-S56 (July 1999)

Slides:



Advertisements
Similar presentations
Volume 72, Issue 7, Pages (October 2007)
Advertisements

Volume 56, Pages S238-S241 (July 1999)
Volume 62, Issue 2, Pages (August 2002)
Volume 66, Issue 6, Pages (December 2004)
Volume 82, Issue 7, Pages (October 2012)
Paraneoplastic glomerulopathies: New insights into an old entity
Volume 76, Pages S3-S11 (December 2009)
Volume 78, Issue 3, Pages (August 2010)
Volume 58, Issue 5, Pages (November 2000)
Volume 82, Issue 7, Pages (October 2012)
Volume 76, Issue 5, Pages (September 2009)
Volume 69, Issue 12, Pages (June 2006)
Volume 68, Issue 6, Pages (December 2005)
Volume 79, Issue 8, Pages (April 2011)
Volume 56, Pages S31-S36 (July 1999)
Volume 68, Issue 2, Pages (August 2005)
Hyun Soon Lee, Young Sook Kim  Kidney International 
Volume 80, Issue 10, Pages (November 2011)
‘Progressive diabetic nephropathy. How useful is microalbuminuria
Volume 66, Issue 3, Pages (September 2004)
Volume 56, Issue 3, Pages (September 1999)
Volume 59, Issue 1, Pages (January 2001)
Apoptosis in the kidneys of patients with type II diabetic nephropathy
Volume 56, Issue 3, Pages (September 1999)
Volume 60, Issue 2, Pages (August 2001)
Tubular biomarkers to assess progression of diabetic nephropathy
Yang Wang, Yi Ping Wang, Yuet-Ching Tay, David C.H. Harris 
Volume 77, Issue 9, Pages (May 2010)
Nrf2-deficient female mice develop lupus-like autoimmune nephritis1
Volume 58, Issue 1, Pages (July 2000)
Mohammed S. Razzaque, Ph.D., Takashi Taguchi  Kidney International 
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Volume 62, Issue 2, Pages (August 2002)
Volume 70, Issue 3, Pages (August 2006)
The epidemiology of chronic kidney disease
Volume 54, Issue 2, Pages (August 1998)
The role of protein kinase C activation in diabetic nephropathy
Volume 72, Issue 3, Pages (August 2007)
Volume 70, Issue 2, Pages (July 2006)
Volume 61, Issue 1, Pages (January 2002)
Glomerular injury is exacerbated in diabetic integrin α1-null mice
Volume 61, Issue 1, Pages (January 2002)
Volume 53, Issue 4, Pages (April 1998)
Volume 68, Issue 3, Pages (September 2005)
Volume 74, Issue 6, Pages (September 2008)
Volume 60, Issue 2, Pages (August 2001)
Volume 72, Issue 7, Pages (October 2007)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Simvastatin in nephrotic syndrome
Lipid-binding proteins in rat and human kidney
The initiation and progression of sickle cell nephropathy
Volume 69, Issue 11, Pages (June 2006)
Volume 71, Issue 4, Pages (February 2007)
Volume 61, Issue 2, Pages (February 2002)
Volume 69, Issue 2, Pages (January 2006)
Volume 73, Issue 3, Pages (February 2008)
Atherosclerotic nephropathy
Volume 55, Pages S3-S16 (June 1999)
Volume 56, Pages S238-S241 (July 1999)
Volume 68, Issue 4, Pages (October 2005)
Volume 63, Issue 1, Pages (January 2003)
Amylin deposition in the kidney of patients with diabetic nephropathy
Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa 
Volume 54, Issue 4, Pages (October 1998)
Volume 56, Issue 2, Pages (August 1999)
The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?  Richard E. Gilbert, Mark E. Cooper  Kidney.
Volume 80, Issue 9, Pages (November 2011)
Unmasking a unique glomerular lesion
Volume 78, Issue 3, Pages (August 2010)
Presentation transcript:

Volume 56, Pages S54-S56 (July 1999) Increased carbonyl modification by lipids and carbohydrates in diabetic nephropathy  Toshio Miyata, M.D., Ph.D, Satoshi Sugiyama, Daisuke Suzuki, Reiko Inagi, Kiyoshi Kurokawa  Kidney International  Volume 56, Pages S54-S56 (July 1999) DOI: 10.1046/j.1523-1755.1999.07114.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Immunohistochemical detection of advanced glycation end product (AGE;A-C) and advanced lipoxidation end product (ALE;D-F) in diabetic glomerular lesions. Both carboxymethyllysine (CML; AGE) and malondialdehyde (MDA)-lysine (ALE) were identified in the expanded mesangial area (A and D) and in nodular lesions (B and E) of diabetic nephropathy, whereas their immunostainings were faint in nondiabetic normal glomeruli (C and F). Anti-AGE mouse monoclonal IgG (6D12), the major epitope structure of which was identified as CML, and anti-MDA-lysine mouse monoclonal IgG (kindly provided from Dr. Joseph L. Witztum) were used for immunohistochemistry. The characterization of the antibodies was described previously4. The specificity of immunostaining was confirmed by competition experiments with either anti-CML or anti-MDA-lysine antibody preincubated with an excess of CML-bovine serum albumin or MDA-bovine serum albumin, respectively (original magnification ×200). Kidney International 1999 56, S54-S56DOI: (10.1046/j.1523-1755.1999.07114.x) Copyright © 1999 International Society of Nephrology Terms and Conditions